EdgeMarket › What Sio Capital Management, Llc reported owning
What Sio Capital Management, Llc reported owning
As filed on Form 13F for the quarter ending 2026-03-31, up to 45 days after that date. Long-only US-listed equity — shorts, bonds, cash and non-US listings are not on the form, so this is one leg of the book, not the book.
Reported value
697.3MPositions
76Quarter
2026-03-31Shown below
50largest by value
| holding | value | % of book | shares | price | 1y |
|---|---|---|---|---|---|
| MMS MAXIMUS, INC. | 49.3M | 7.1% | 768.8K | 58.22 | -31.7% |
| WAY Waystar Holding Corp. | 39.6M | 5.7% | 1.6M | 25.01 | -28.7% |
| ICLR ICON PLC | 33.9M | 4.9% | 306.4K | 172.23 | -4.4% |
| COR Cencora, Inc. | 31.7M | 4.5% | 100.9K | 318.04 | +4.7% |
| DNTH Dianthus Therapeutics, Inc. /DE/ | 31.1M | 4.5% | 370.0K | 111.10 | +374.4% |
| AVR Anteris Technologies Global Corp. | 29.9M | 4.3% | 5.4M | 8.98 | +152.2% |
| CORT CORCEPT THERAPEUTICS INC | 27.2M | 3.9% | 674.8K | 122.25 | +73.7% |
| LIVN LivaNova PLC | 26.8M | 3.8% | 421.6K | 78.74 | +47.5% |
| TYRA Tyra Biosciences, Inc. | 23.2M | 3.3% | 605.4K | 26.05 | +154.4% |
| CELC Celcuity Inc. | 22.1M | 3.2% | 193.8K | 93.53 | +91.8% |
| GSK GSK plc | 21.3M | 3.1% | 385.9K | 52.41 | +30.8% |
| ANIP ANI PHARMACEUTICALS INC | 20.4M | 2.9% | 265.5K | 75.35 | -16.9% |
| ABT ABBOTT LABORATORIES | 19.2M | 2.7% | 186.6K | 116.64 | -11.9% |
| EMBC Embecta Corp. | 16.3M | 2.3% | 1.8M | 5.23 | -62.3% |
| ABVX Abivax S.A. | 15.1M | 2.2% | 135.8K | 114.95 | +59.9% |
| VIR Vir Biotechnology, Inc. | 13.4M | 1.9% | 1.5M | 9.78 | +124.3% |
| HAE HAEMONETICS CORP | 12.4M | 1.8% | 220.7K | 108.80 | +99.8% |
| SION Sionna Therapeutics, Inc. | 11.8M | 1.7% | 294.3K | 5.29 | -76.8% |
| SNY Sanofi | 11.5M | 1.7% | 239.7K | 45.85 | -9.3% |
| RAPP Rapport Therapeutics, Inc. | 11.5M | 1.6% | 366.8K | 48.24 | +236.9% |
| TFX TELEFLEX INC | 11.3M | 1.6% | 94.8K | 138.83 | +10.5% |
| BMRN BIOMARIN PHARMACEUTICAL INC | 11.0M | 1.6% | 194.2K | 66.70 | +15.1% |
| unmapped CUSIP 227483104 | 10.3M | 1.5% | 1.1M | — | — |
| TARA Protara Therapeutics, Inc. | 10.3M | 1.5% | 2.0M | 3.85 | +27.1% |
| GPCR Structure Therapeutics Inc. | 10.1M | 1.4% | 209.1K | 49.09 | +164.4% |
| BHVN Biohaven Ltd. | 9.8M | 1.4% | 1.2M | 13.85 | -5.8% |
| MNPR Monopar Therapeutics | 9.5M | 1.4% | 173.5K | 107.72 | +226.4% |
| EYPT EyePoint, Inc. | 9.3M | 1.3% | 721.8K | 5.32 | -53.8% |
| CRNX Crinetics Pharmaceuticals, Inc. | 9.1M | 1.3% | 249.9K | 84.69 | +191.1% |
| EWTX Edgewise Therapeutics, Inc. | 8.5M | 1.2% | 269.0K | 44.18 | +219.2% |
| CMPS COMPASS Pathways plc | 8.3M | 1.2% | 1.5M | 13.33 | +226.7% |
| OCUL OCULAR THERAPEUTIX, INC | 8.2M | 1.2% | 968.6K | 11.08 | -7.4% |
| AQST Aquestive Therapeutics, Inc. | 8.0M | 1.1% | 1.9M | 4.66 | +20.1% |
| RLMD RELMADA THERAPEUTICS, INC. | 6.7M | 1.0% | 965.0K | 4.63 | +655.9% |
| ORKA Oruka Therapeutics, Inc. | 6.5M | 0.9% | 132.5K | 107.96 | +649.7% |
| ZBIO Zenas BioPharma, Inc. | 6.5M | 0.9% | 331.7K | 32.29 | +97.9% |
| DRUG BRIGHT MINDS BIOSCIENCES INC. | 6.3M | 0.9% | 86.1K | 77.42 | +80.0% |
| QDEL QuidelOrtho Corp | 5.9M | 0.8% | 359.0K | 14.74 | -44.0% |
| ZBH ZIMMER BIOMET HOLDINGS, INC. | 5.7M | 0.8% | 62.6K | 100.98 | -4.5% |
| REPL Replimune Group, Inc. | 5.5M | 0.8% | 720.0K | 14.77 | +181.3% |
| OGN Organon & Co. | 5.2M | 0.7% | 865.9K | 13.75 | +46.7% |
| OKUR OnKure Therapeutics, Inc. | 4.5M | 0.6% | 1.1M | 3.94 | +44.3% |
| IRON Disc Medicine, Inc. | 4.2M | 0.6% | 65.2K | 79.81 | +35.9% |
| PMVP PMV Pharmaceuticals, Inc. | 3.8M | 0.5% | 3.1M | 1.33 | -10.1% |
| IMNM Immunome Inc. | 3.6M | 0.5% | 165.1K | 28.52 | +198.0% |
| IART INTEGRA LIFESCIENCES HOLDINGS CORP | 3.6M | 0.5% | 383.1K | 16.74 | +17.4% |
| SVRA Savara Inc | 3.4M | 0.5% | 613.9K | 5.59 | +80.9% |
| PRQR ProQR Therapeutics N.V. | 3.2M | 0.5% | 2.0M | 2.34 | +9.3% |
| SI SHOULDER INNOVATIONS, INC. | 3.1M | 0.4% | 210.6K | 22.06 | +82.3% |
| OVID Ovid Therapeutics Inc. | 2.8M | 0.4% | 1.3M | 2.80 | +194.7% |
A position that grew quarter on quarter may simply reflect a higher price: if the stock rose 40% and the manager did nothing, the reported value rose 40%. Reading that as accumulation is reading the price back to yourself. More on that →
The whole archive is one click away.
Screener, filings, insider flow, backtests and the AI — open without an account.
Free plan for good. Pro is $69.99/mo, or $4.99 for a 7-day trial. See the plans →